mail
editor@ajptr.com
whatsapp
9409046853
logo

American Journal of PharmTech Research

Published

RP-HPLC Method Development and Validation of Desvenlafaxine Succinate Monohydrate in Tablet Dosage Form

Published in August 2014 Issue 4 (Vol. 4, Issue 4, 2014)

RP-HPLC Method Development and Validation of Desvenlafaxine Succinate Monohydrate in Tablet Dosage Form - Issue cover

Abstract

The objective of this work was to develop and validate simple, rapid and accurate chromatographic method for determination of Desvenlafaxine succinate in solid dosage form. This RP-HPLC method was based on Reversed Phase High Performance Liquid Chromatography, on ODS C18 RP column (250 mm × 4.6 mm i.d., 5 μ), using Acetonitrile: Ammonium Phosphate buffer (pH 3.0) (70:30 v/v) as the mobile phase, at a flow rate of 1 mL/min at ambient temperature. Quantification was achieved by UV detection at 220 nm over a concentration range of 20-160 μg/mL for Desvenlafaxine succinate. The mean retention time for Desvenlafaxine succinate was found to be 2.44 min. The amount of Desvenlafaxine succinate estimated as percentage label claim was found to be 99.67. Key words: RP-HPLC, Desvenlafaxine succinate, marketed formulation.

Authors (2)

Download Article

PDF

Best for printing and citation

File size: 0.0 MB
Format: PDF

Download Article

PDF

Best for printing and citation

File size: 0.0 MB
Format: PDF

Article Information

Article ID:
AJPTR44060
Paper ID:
AJPTR-01-002338
Published Date:
2014-08-01

Article Impact

Views:4,056
Downloads:1,280

How to Cite

Pingle & Salunkhe (2014). RP-HPLC Method Development and Validation of Desvenlafaxine Succinate Monohydrate in Tablet Dosage Form. American Journal of PharmTech Research, 4(4), xx-xx. https://ajptr.scholarjms.com/articles/1236

Article Actions

Whatsapp